Associate Professor of Neurology and Epidemiology
2007 PhD Epidemiology, UAB School of Public Health
2005 MSPH, UAB School of Public Health
1994 PharmD, Samford University
Office: JT 1235, 619 South 19th Street, Birmingham AL 35249
Dr. Nita Limdi is a Clinical Pharmacist and Epidemiologist in the Department of Neurology working in collaboration with the UAB Epilepsy Center. Her subspecialty is Pharmacogenetics/ genomics, Pharmacoepidemiology and Neuropharmacology. The primary focus of her research is to elucidate genetic and environmental determinants of drug response, specifically those that are associated with toxicity and lack of efficacy. Currently her research efforts focus on understanding the genetic and environmental regulation of warfarin response and using this information to individualize therapy to reduce the risk of hemorrhagic complications. This effort will set the stage for identifying predictors of response to other widely used drugs.
After receiving a Bachelor of Science degree in Pharmacy from Sardar Patel University, India (1988), she then obtained a Bachelor of Science degree in Pharmacy from Samford University, Birmingham, AL (1993). Dr. Limdi then went on to complete a pharmacy internship at Samford from 1993-1994, completing her PharmD in 1994. She became a Clinical Pharmacist with UAB from 1994-1997 and a Clinical Pharmacy Specialist in Neurosciences at UAB from 1997-2003. To enhance her clinical research skills, she continued her education obtaining a MSPH (Clinical research/ Biostatistics) in 2005 and a PhD in Epidemiology in 2007. Dr. Limdi was appointed Adjunct Assistant Professor with the Department of Neurology in 2001 and Assistant Professor in 2003. Dr. Limdi has a secondary appointment in the Department of Epidemiology.
- Pharmacogenetic Optimization of Anticoagulation Therapy (funded by NINDS)
- Genetic and Environmental Determinants of Warfarin Response (funded by NHLBI)
- Comparative efficacy and tolerability of Levetiracetam and Phenytoin in patients with Brain tumors (funded by UCB Pharma)
- Safety, efficacy and pharmacokinetics of valproic acid following rapid intravenous administration of DepaconTM injection. (Funded by Abbott Laboratories, IND# 62165)
- Role of valproic acid in the treatment of Status Epilepticus (Funded by Abbott Laboratories)
- Safety of rapid valproic acid infusion (Funded by Abbott Laboratories)
Specialty / Interests
- Recipient of the Irtaza and Shana Siddique Endowed Award for Academic Excellence in Epidemiology. University of Alabama at Birmingham. May 2008.
- Recipient of Award to Young Investigators Central Society for Clinical Research meeting, Chicago, IL. 2008
Neuropharmacology: Antiepileptic drugs, treatment of status epilepticus.
Pharmacogenetics, pharmacogenomics, and genetic epidemiology. Publications in PubMed